BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen K, Gorgen A, Ding A, Du L, Jiang K, Ding Y, Sapisochin G, Ghanekar A. Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma. Hepatol Commun 2021;5:1310-28. [PMID: 34278178 DOI: 10.1002/hep4.1701] [Reference Citation Analysis]
2 Buechler C, Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158658. [PMID: 32058031 DOI: 10.1016/j.bbalip.2020.158658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
3 Feder S, Bruckmann A, McMullen N, Sinal CJ, Buechler C. Chemerin Isoform-Specific Effects on Hepatocyte Migration and Immune Cell Inflammation. Int J Mol Sci 2020;21:E7205. [PMID: 33003572 DOI: 10.3390/ijms21197205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
5 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Reference Citation Analysis]
7 Kudo M. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer 2021;10:167-80. [PMID: 34239807 DOI: 10.1159/000516491] [Reference Citation Analysis]
8 Hosseini K, Ranjbar M, Pirpour Tazehkand A, Asgharian P, Montazersaheb S, Tarhriz V, Ghasemnejad T. Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing. J Transl Med 2022;20:30. [PMID: 35033106 DOI: 10.1186/s12967-022-03231-y] [Reference Citation Analysis]
9 Tsilimigras DI, Hyer JM, Diaz A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:747. [PMID: 33670174 DOI: 10.3390/cancers13040747] [Reference Citation Analysis]
10 Rodriguez S, Skeet K, Mehmetoglu-Gurbuz T, Goldfarb M, Karri S, Rocha J, Shahinian M, Yazadi A, Poudel S, Subramani R. Phytochemicals as an Alternative or Integrative Option, in Conjunction with Conventional Treatments for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5753. [PMID: 34830907 DOI: 10.3390/cancers13225753] [Reference Citation Analysis]
11 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
12 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
13 Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2021:S0168-8278(21)02100-0. [PMID: 34648895 DOI: 10.1016/j.jhep.2021.09.035] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li XQ, Wang X, Zhao DW, Sun J, Liu JJ, Lin DD, Yang G, Liu H, Xia ZY, Jia CY, Li HJ. Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma. World J Surg Oncol 2020;18:219. [PMID: 32828123 DOI: 10.1186/s12957-020-01996-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sun C, Li R, Song Y, Jiang X, Zhang C, Cheng S, Hu W. Ultrasensitive and Reliable Organic Field-Effect Transistor-Based Biosensors in Early Liver Cancer Diagnosis. Anal Chem 2021;93:6188-94. [DOI: 10.1021/acs.analchem.1c00372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wu D, Pan Y, Zheng X. Identification of hub genes-based predictive model in hepatocellular carcinoma by robust rank aggregation and regression analysis. J Cancer 2021;12:1884-93. [PMID: 33753986 DOI: 10.7150/jca.52089] [Reference Citation Analysis]
17 Mao X, Guo Y, Lu Z, Wen F, Liang H, Sun W. Enhanced CT Textures Derived From Computer Mathematic Distribution Analysis Enables Arterial Enhancement Fraction Being an Imaging Biomarker Option of Hepatocellular Carcinoma. Front Oncol 2020;10:1337. [PMID: 32850426 DOI: 10.3389/fonc.2020.01337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clin Imaging 2021;76:123-9. [PMID: 33592550 DOI: 10.1016/j.clinimag.2021.01.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs 2020;80:315-22. [DOI: 10.1007/s40265-020-01263-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
20 Wang W, Cai X, Li Q, Zheng L, Yu X, Zhang H, Wang J. Application of a microfluidic paper-based bioimmunosensor with laser-induced fluorescence detection in the determination of alpha-fetoprotein from serum of hepatopaths. Talanta 2021;221:121660. [DOI: 10.1016/j.talanta.2020.121660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D'yachkova Y, Lukanowski M, Cheng R, Chen LT. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers? Cancers (Basel) 2021;13:3536. [PMID: 34298750 DOI: 10.3390/cancers13143536] [Reference Citation Analysis]
22 Chen D, Feng Z, Zhou M, Ren Z, Zhang F, Li Y. Bioinformatic Evidence Reveals that Cell Cycle Correlated Genes Drive the Communication between Tumor Cells and the Tumor Microenvironment and Impact the Outcomes of Hepatocellular Carcinoma. Biomed Res Int 2021;2021:4092635. [PMID: 34746301 DOI: 10.1155/2021/4092635] [Reference Citation Analysis]
23 Li S, Liu X, Liu S, Guo M, Liu C, Pei M. Fluorescence sensing strategy based on aptamer recognition and mismatched catalytic hairpin assembly for highly sensitive detection of alpha-fetoprotein. Anal Chim Acta 2021;1141:21-7. [PMID: 33248654 DOI: 10.1016/j.aca.2020.10.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
25 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Leeming DJ, Nielsen SH, Vongsuvanh R, Uchila P, Nielsen MJ, Reese-Petersen AL, van der Poorten D, Eslam M, Schuppan D, Karsdal MA, George J. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepat Oncol 2020;8:HEP32. [PMID: 34084451 DOI: 10.2217/hep-2020-0030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 2021;124:1388-97. [PMID: 33531690 DOI: 10.1038/s41416-021-01260-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wu Z, Xu Z, Yu B, Zhang J, Yu B. The Potential Diagnostic Value of Exosomal Long Noncoding RNAs in Solid Tumors: A Meta-Analysis and Systematic Review. Biomed Res Int 2020;2020:6786875. [PMID: 32879887 DOI: 10.1155/2020/6786875] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Fowler KJ, Burgoyne A, Fraum TJ, Hosseini M, Ichikawa S, Kim S, Kitao A, Lee JM, Paradis V, Taouli B, Theise ND, Vilgrain V, Wang J, Sirlin CB, Chernyak V. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics 2021;41:1611-31. [PMID: 34597222 DOI: 10.1148/rg.2021210009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dai Z, Wang K, Gao Y. The critical role of B4GALT4 in promoting microtubule spindle assembly in HCC through the regulation of PLK1 and RHAMM expression. J Cell Physiol 2021. [PMID: 34270095 DOI: 10.1002/jcp.30531] [Reference Citation Analysis]
31 Singh R. Nanotechnology based therapeutic application in cancer diagnosis and therapy. 3 Biotech 2019;9:415. [PMID: 31696020 DOI: 10.1007/s13205-019-1940-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
32 Kunadirek P, Ariyachet C, Sriphoosanaphan S, Pinjaroen N, Sirichindakul P, Nookaew I, Chuaypen N, Tangkijvanich P. Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Sci Rep 2021;11:11201. [PMID: 34045534 DOI: 10.1038/s41598-021-90515-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lorenzo-Gómez R, González-Robles D, Miranda-Castro R, de-Los-Santos-Álvarez N, Lobo-Castañón MJ. On the Electrochemical Detection of Alpha-Fetoprotein Using Aptamers: DNA Isothermal Amplification Strategies to Improve the Performance of Weak Aptamers. Biosensors (Basel) 2020;10:E46. [PMID: 32365872 DOI: 10.3390/bios10050046] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Liu Z, Zhang Z, Mei H, Mao J, Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int 2020;14:544-55. [PMID: 32504407 DOI: 10.1007/s12072-020-10056-8] [Reference Citation Analysis]
35 Gupta S, Khan S, Kawka M, Gujjuri R, Chau I, Starling N, Cunningham D, Jiao LR, Gall T. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34402366 DOI: 10.1080/17474124.2021.1967144] [Reference Citation Analysis]
36 Bedon L, Dal Bo M, Mossenta M, Busato D, Toffoli G, Polano M. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. Int J Mol Sci 2021;22:1075. [PMID: 33499054 DOI: 10.3390/ijms22031075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Bai C, Wang H, Dong D, Li T, Yu Z, Guo J, Zhou W, Li D, Yan R, Wang L, Wang Z, Li Y, Ren L. Urea as a By-Product of Ammonia Metabolism Can Be a Potential Serum Biomarker of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:650748. [PMID: 33869206 DOI: 10.3389/fcell.2021.650748] [Reference Citation Analysis]
38 Luo X, Cui H, Cai L, Zhu W, Yang WC, Patrick M, Zhu S, Huang J, Yao X, Yao Y, He Y, Ji Y. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit. Front Immunol 2020;11:623. [PMID: 32425926 DOI: 10.3389/fimmu.2020.00623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, Abate ML, Risso A, Ribaldone DG, Tandoi F, Saracco GM, Bugianesi E, Gaia S. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2776. [PMID: 32998218 DOI: 10.3390/cancers12102776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
41 Chen W, Mao Y, Liu C, Wu H, Chen S. Exosome in Hepatocellular Carcinoma: an update. J Cancer 2021;12:2526-36. [PMID: 33854614 DOI: 10.7150/jca.54566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021;11:6069. [PMID: 33727662 DOI: 10.1038/s41598-021-85688-3] [Reference Citation Analysis]
43 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
44 Cohn DE, Barros-Filho MC, Minatel BC, Pewarchuk ME, Marshall EA, Vucic EA, Sage AP, Telkar N, Stewart GL, Jurisica I, Reis PP, Robinson WP, Lam WL. Reactivation of Multiple Fetal miRNAs in Lung Adenocarcinoma. Cancers (Basel) 2021;13:2686. [PMID: 34072436 DOI: 10.3390/cancers13112686] [Reference Citation Analysis]
45 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
46 Pelizzaro F, Cardin R, Sartori A, Imondi A, Penzo B, Aliberti C, Ponzoni A, Vitale A, Cillo U, Farinati F. Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. Biomedicines 2021;9:890. [PMID: 34440094 DOI: 10.3390/biomedicines9080890] [Reference Citation Analysis]
47 Lin K, Huang Q, Zeng J, Ding Z, Wang L, Chen Z, Guo P, Zeng Y, Zhou W, Liu J. Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection. Dig Dis Sci 2021. [PMID: 33723698 DOI: 10.1007/s10620-020-06797-z] [Reference Citation Analysis]
48 Cabibbo G, Singal AG. The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)02226-1. [PMID: 34843751 DOI: 10.1016/j.jhep.2021.11.021] [Reference Citation Analysis]
49 Ridder DA, Weinmann A, Schindeldecker M, Urbansky LL, Berndt K, Gerber TS, Lang H, Lotz J, Lackner KJ, Roth W, Straub BK. Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma. Int J Cancer 2021. [PMID: 34894400 DOI: 10.1002/ijc.33898] [Reference Citation Analysis]
50 Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1195-207. [PMID: 34595140 DOI: 10.2147/JHC.S322289] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, Wood C, Assenmacher CA, Merricks EP, Long CT, Kazazian HH, Nichols TC, Bushman FD, Sabatino DE. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol 2021;39:47-55. [PMID: 33199875 DOI: 10.1038/s41587-020-0741-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
52 Zhu Z, West GR, Wang DC, Collins AB, Xiao H, Bai Q, Mesfin FB, Wakefield MR, Fang Y. AFP peptide (AFPep) as a potential growth factor for prostate cancer. Med Oncol 2021;39:2. [PMID: 34739644 DOI: 10.1007/s12032-021-01598-4] [Reference Citation Analysis]
53 Zumpano R, Polli F, D’agostino C, Antiochia R, Favero G, Mazzei F. Nanostructure-Based Electrochemical Immunosensors as Diagnostic Tools. Electrochem 2021;2:10-28. [DOI: 10.3390/electrochem2010002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020;26:4795-804. [PMID: 32636319 DOI: 10.1158/1078-0432.CCR-19-3884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
55 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Reference Citation Analysis]
56 Li W, Chen M, Liang J, Lu C, Zhang M, Hu F, Zhou Z, Li G. Electrochemical aptasensor for analyzing alpha-fetoprotein using RGO-CS-Fc nanocomposites integrated with gold-platinum nanoparticles. Anal Methods 2020;12:4956-66. [PMID: 33000769 DOI: 10.1039/d0ay01465f] [Reference Citation Analysis]
57 Negri F, Gnetti L, Pedrazzi G, Silini EM, Porta C. Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance? Future Oncol 2021;17:3579-84. [PMID: 34155918 DOI: 10.2217/fon-2021-0083] [Reference Citation Analysis]
58 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Reference Citation Analysis]
59 Zhang K, Fang T, Shao Y, Wu Y. TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 Signaling Axis Promotes Viability, Migration, Invasion and EMT of Hepatocellular Carcinoma Cells. Cancer Manag Res 2021;13:7087-99. [PMID: 34531686 DOI: 10.2147/CMAR.S297765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation. Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study. Clin Chem Lab Med 2021. [PMID: 33964202 DOI: 10.1515/cclm-2021-0283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Ellero AA, van den Bout I, Vlok M, Cromarty AD, Hurrell T. Continual proteomic divergence of HepG2 cells as a consequence of long-term spheroid culture. Sci Rep 2021;11:10917. [PMID: 34035320 DOI: 10.1038/s41598-021-89907-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Liang L, Wang MD, Zhang YM, Zhang WG, Zhang CW, Lau WY, Shen F, Pawlik TM, Huang DS, Yang T. Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml). J Hepatocell Carcinoma 2021;8:103-18. [PMID: 33748017 DOI: 10.2147/JHC.S289840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhang K, Tao C, Siqin T, Wu J, Rong W. Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion. J Transl Med 2021;19:293. [PMID: 34229698 DOI: 10.1186/s12967-021-02940-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Wang L, Li Q, Zhang J, Lu J. A Novel Prognostic Scoring Model Based on Albumin and γ-Glutamyltransferase for Hepatocellular Carcinoma Prognosis. Cancer Manag Res 2019;11:10685-94. [PMID: 31920379 DOI: 10.2147/CMAR.S232073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
66 He JJ, Shang L, Yu QW, Jiao N, Qiu S, Zhu WX, Wu DF, Tian YE, Zhang Q. High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation. World J Gastrointest Oncol 2021; 13(7): 716-731 [PMID: 34322200 DOI: 10.4251/wjgo.v13.i7.716] [Reference Citation Analysis]
67 Khazamipour N, Al-Nakouzi N, Oo HZ, Ørum-Madsen M, Steino A, Sorensen PH, Daugaard M. Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors. Cells 2020;9:E818. [PMID: 32231047 DOI: 10.3390/cells9040818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
68 Pathak S, Sonbol MB. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. J Hepatocell Carcinoma 2021;8:1147-58. [PMID: 34584898 DOI: 10.2147/JHC.S268314] [Reference Citation Analysis]
69 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021;2:836-850.e10. [PMID: 34318286 DOI: 10.1016/j.medj.2021.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
70 He R, Li J, He W, Chen G, Huang Z, Li M, Wu W, Chen J, Pan Y, Jiang H, Dang Y, Yang L. Prognosis prediction ability and prospective biological mechanisms of WDHD1 in hepatocellular carcinoma tissues. Electronic Journal of Biotechnology 2022;55:78-90. [DOI: 10.1016/j.ejbt.2021.12.001] [Reference Citation Analysis]
71 Zhong Y, Qi H, Li X, An M, Shi Q, Qi J. Tumor supernatant derived from hepatocellular carcinoma cells treated with vincristine sulfate have therapeutic activity. Eur J Pharm Sci 2020;155:105557. [PMID: 32946955 DOI: 10.1016/j.ejps.2020.105557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Ye F, Huang W, Xue Y, Tang E, Wang M, Shi F, Wei D, Han Y, Chen P, Zhang X, Yu D. Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:285-300. [PMID: 33948441 DOI: 10.2147/JHC.S306966] [Reference Citation Analysis]
73 Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, Dulundu E, Uzun S, Colombatto P, Oliveri F, Brunetto MR, Gunduz F. Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. Hepatol Commun 2021. [PMID: 34751001 DOI: 10.1002/hep4.1836] [Reference Citation Analysis]
74 Haberl EM, Pohl R, Rein-Fischboeck L, Feder S, Sinal CJ, Bruckmann A, Hoering M, Krautbauer S, Liebisch G, Buechler C. Overexpression of Hepatocyte Chemerin-156 Lowers Tumor Burden in a Murine Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma. Int J Mol Sci 2019;21:E252. [PMID: 31905933 DOI: 10.3390/ijms21010252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
75 Huan L. Efficacy analysis of combined detection of 5 Serological Tumor markers including MIF and PIVKA-II for early diagnosis of Primary Hepatic Cancer. Pak J Med Sci 2021;37:1456-60. [PMID: 34475930 DOI: 10.12669/pjms.37.5.4264] [Reference Citation Analysis]
76 Liu S, Yu G, Liu L, Zou X, Zhou L, Hu E, Song Y. Identification of Prognostic Stromal-Immune Score-Based Genes in Hepatocellular Carcinoma Microenvironment. Front Genet 2021;12:625236. [PMID: 33643387 DOI: 10.3389/fgene.2021.625236] [Reference Citation Analysis]
77 Wang W, Zhu G, Lai S, Guo Y, Yin X, Chen D, Wen L. Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1) Acts as Diagnostic Biomarker and Adverse Prognostic Factor of Hepatocellular Carcinoma (HCC): Evidence from Bioinformatic Analysis. Med Sci Monit 2020;26:e919896. [PMID: 32090983 DOI: 10.12659/MSM.919896] [Reference Citation Analysis]
78 Possner M, Gordon-Walker T, Egbe AC, Poterucha JT, Warnes CA, Connolly HM, Ginde S, Clift P, Kogon B, Book WM, Walker N, Wagenaar LJ, Moe T, Oechslin E, Kay WA, Norris M, Dillman JR, Trout AT, Anwar N, Hoskoppal A, Broering DC, Bzeizi K, Veldtman G. Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes. Int J Cardiol 2021;322:142-8. [PMID: 32828959 DOI: 10.1016/j.ijcard.2020.08.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
79 Usha SP, Manoharan H, Deshmukh R, Álvarez-Diduk R, Calucho E, Sai VVR, Merkoçi A. Attomolar analyte sensing techniques (AttoSens): a review on a decade of progress on chemical and biosensing nanoplatforms. Chem Soc Rev 2021;50:13012-89. [PMID: 34673860 DOI: 10.1039/d1cs00137j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Wu D, Zhang R, Zhan L. Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile. Clin Res Hepatol Gastroenterol 2021;46:101812. [PMID: 34597849 DOI: 10.1016/j.clinre.2021.101812] [Reference Citation Analysis]
81 Chen T, Dai X, Dai J, Ding C, Zhang Z, Lin Z, Hu J, Lu M, Wang Z, Qi Y, Zhang L, Pan R, Zhao Z, Lu L, Liao W, Lu X. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020;11:822. [PMID: 33009373 DOI: 10.1038/s41419-020-03030-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]